(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX was host to an Advanced Disease and Adjuvant Therapy session. Dr. Jean Hoffman-Censits discussed the ...
Overall, the median real world time on treatment for earliest olaparib monotherapy 4.6 months (95% CI 3.5 - 5.5), for patients with less than 3 lines of therapy was 5.3 months (95% CI 4.0 – 8.2), and ...
The most common situation where pN0 pathology was found was in smaller, equivocal nodes between 1-1.5cm, and in the SEMS trial, 30% of patients with nodes of this size were pN0. To date, there have ...
(UroToday.com) The 2024 SUO annual meeting included a session on smoking cessation, vaping, and e-cigarettes, featuring a presentation by Dr. Marc Bjurlin discussing e-cigarette use and the risk of ...
Dr. Scott Tagawa presented ProstACT GLOBAL, a phase III study of best SOC with or without 177 Lu-DOTA-rosopatamab (TLX591) for patients with PSMA-expressing mCRPC who experienced disease progression ...
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX was host to an Advanced Disease and Adjuvant Therapy session. Dr. Omar Mian discussed the role of adjuvant ...
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Course and the session Metastatic ...
(UroToday.com)The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Course and the Session Muscle Invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback